At present, the best‐known therapeutics used in clinic for CRC treatment include bevacizumab, cetuximab and panitumumab, which target vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR) and epidermal growth factor receptor (EGFR) (Falchook and Kurzrock, 2015; Saucier and Rivard, 2010). The gene discussed is VEGFA; the disease is colorectal carcinoma.